Advertisement

Topics

Mavacamten shows promise for treating patients with obstructive hypertrophic cardiomyopathy

12:00 EDT 10 May 2019 | 2 Minute Medicine

1. In this open-label clinical trial, mavacamten was found to reduce mean postexercise left ventricular outflow tract gradient after 12 weeks of treatment, which was accompanied by improvements in patient exercise capacity and cardiac symptoms. 2. The most common adverse events related to treatment with mavacamten were reduced left ventricular ejection fraction and atrial fibrillation […]
Source: 2 Minute Medicine

Original Article: Mavacamten shows promise for treating patients with obstructive hypertrophic cardiomyopathy

NEXT ARTICLE

More From BioPortfolio on "Mavacamten shows promise for treating patients with obstructive hypertrophic cardiomyopathy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...